The IL28B RealFast™ Assay helps to predict the success of antiviral therapy and sustained virologic response (SVR) in Hepatitis C Virus (HCV) infected patients.
IL28B
Direct-acting antivirals and pegylated Interferon/Ribavirin regimens are used for the treatment of HCV infection.
SVR is dependent on virus genotype and on patients’ factors like age, sex, ethnicity and genetic variants associated with antiviral activity.
The functional variant rs368234815 TT>ΔG regulating IL28B expression is the strongest known host factor for predicting HCV clearance.
Genotyping of rs368234815 TT>ΔG helps to predict spontaneous and treatment-induced viral clearance in patients independent of their ethnicity.
